Anxiety and depression coexist in roughly 50 percent of patients with either condition, based on data from the National Comorbidity Survey Replication summarized by the National Institute of Mental Health and by the Anxiety and Depression Association of America. The combination tends to produce longer episodes, more functional impairment, and higher suicide risk than either alone. Treatment generally addresses both, often with an SSRI or SNRI plus therapy. The order of which to treat first matters less than recognizing that both need explicit attention; treating only one and assuming the other will lift on its own is a common reason patients fail to improve.
Anxiety and depression are clinically distinct, but in practice they live together more often than apart. Recognizing the combination matters because it changes the prognosis, the treatment plan, and the level of follow-up needed.
The comorbidity is the rule, not the exception
Population studies consistently find high overlap. Roughly half of patients with major depression also meet criteria for an anxiety disorder. Roughly half of patients with generalized anxiety disorder also meet criteria for depression. The lifetime overlap is higher still.
The conditions share some neurobiology, both involve dysregulation in serotonergic and noradrenergic signaling, both affect prefrontal-amygdala circuits, but they aren't the same disorder. The distinction is in the phenomenology.
Depression is dominated by low mood and loss of interest, with neurovegetative changes (sleep, appetite, energy, concentration, psychomotor changes). Anxiety is dominated by sustained worry and physiological activation, with somatic features (muscle tension, autonomic arousal, sleep onset difficulty). When both are present, the patient typically describes a mix: the worry of anxiety and the heaviness of depression at the same time.
Why the combination is harder
Several specific features.
Longer episodes. Patients with anxious depression tend to have longer episodes than patients with pure depression. The anxiety component appears to prolong the depressive episode.
More functional impairment. The combination produces more disability than either alone, with worse outcomes on work productivity, social engagement, and self-care.
Higher suicide risk. This is the most clinically important point. Anxious depression carries higher suicide risk than depression alone. The combination of hopelessness (from depression) and high arousal (from anxiety) is particularly dangerous. Patients with mixed anxiety and depression who report suicidal thoughts deserve careful evaluation and active treatment.
More treatment resistance. Patients with anxious depression often respond less well to initial antidepressant trials than patients with non-anxious depression. Multiple medication trials are more common before reaching adequate response.
Sleep problems are worse. The combination tends to produce both difficulty falling asleep (the anxiety pattern) and early-morning waking (the depression pattern), often in the same patient.
Treatment when both are present
The good news: most of the same treatments work for both conditions, which simplifies the regimen.
SSRIs and SNRIs. Both classes have evidence for both depression and anxiety. The choice of agent depends on the patient's specific picture: sertraline and escitalopram are often first-line for anxious depression. venlafaxine and duloxetine (SNRIs) are also reasonable choices, particularly when fatigue is prominent or when there's co-occurring chronic pain.
CBT. Cognitive behavioral therapy works for both. Adaptations specific to anxious depression often combine behavioral activation (the depression piece) with anxiety-focused work (cognitive restructuring, exposure where relevant). Most CBT therapists can address both within a single course of treatment.
Combination treatment. For moderate-to-severe anxious depression, the combination of medication plus therapy tends to outperform either alone. The medication addresses the underlying reactivity; the therapy builds skills and addresses behavioral patterns.
Treating the depression first, in some cases. When depression is severe enough that the patient can't engage in active therapy work, starting with medication to lift the depression enough to participate in therapy is often the right sequence.
Treating the anxiety first, in other cases. When anxiety is the dominant symptom and is driving the depression (the patient has been worn down by years of anxiety), addressing the anxiety first may resolve much of the depression.
The decision is made in the clinical conversation, taking into account symptom severity, the patient's preferences, and what has worked previously.
A specific clinical caution: bipolar depression
One of the most consequential diagnostic distinctions in this space. A patient who presents with anxious depression should be asked carefully about any prior episodes of elevated mood, periods of unusually high energy, reduced sleep need, increased goal-directed activity, racing thoughts in a generative rather than worry-driven sense, impulsive behaviors. These can suggest underlying bipolar disorder, where the current presentation is a depressive episode rather than unipolar depression.
The treatment differs substantially. Antidepressants used alone in bipolar depression can sometimes precipitate manic or hypomanic episodes or rapid cycling. Mood stabilizers or atypical antipsychotics specifically approved for bipolar depression are the appropriate first-line treatments.
Missing this distinction is one of the more common errors in primary care psychiatric prescribing. A patient with treatment-resistant depression and a personal or family history of mood elevation deserves careful evaluation for bipolar disorder.
What doesn't work as well as people hope
A few patterns:
Treating the anxiety only and assuming the depression will lift. Sometimes it does; often it doesn't. Both deserve explicit attention.
Treating with benzodiazepines as the primary anxiolytic. The combination of depression and benzodiazepines tends to produce worse outcomes over time, with higher rates of suicidal ideation and lower rates of recovery.
Brief or supportive therapy without a structured approach. Patients with anxious depression generally do better with structured CBT or similar evidence-based approaches than with open-ended supportive work.
Single-modality trials without reassessment. A patient who has been on a single SSRI at a single dose for 3 to 4 months without meaningful improvement deserves a treatment adjustment, not continued monitoring. Mirtazapine is sometimes added in this scenario, particularly when sleep and appetite are also affected.
Companion coverage on depression
For deeper coverage of depression specifically, see the companion page on depression with anxious features at DepressionResource. It covers the diagnostic picture, treatment adjustments, and prognosis when the two present together. For depression more broadly, including diagnostic criteria, treatment options, and life-stage variants of major depressive disorder, see DepressionResource.org. Both properties are medically reviewed by the same psychiatrist and follow the same editorial standards.
For more on why the two so often travel together, see what causes depression and anxiety on shrinkMD. (shrinkMD is part of The Shrink Network, founded by Shariq Refai, MD, MBA.)
External citations
The NIMH page on co-occurring depression and anxiety covers the basics. The APA practice guideline for depression and the Cochrane review on combined treatment discuss the evidence for combined approaches.
For the clinical encyclopedia entry on this condition, see Shrinkopedia →